bilaterals.org logo
bilaterals.org logo

medicines


India-UK FTA leaked draft reveals nobody’s gain except big pharma
India - UK FTA provisions favor neither India nor the UK except the pharma industry in a big way. It defeats the firm stand taken by the Indian PM three years ago when he decided to pull out of the RCEP against the corporate interests over people’s lives.
MSF responds to UK’s disastrous proposal on intellectual property in UK-India Free Trade Agreement
UK IP demands contain provisions that would drastically harm access to affordable, lifesaving generic medicines from India, upon which millions of people around the world rely.
WTO COVID IP negotiating text as of 25/5/2022
Consolidated negotiating COVID intellectual property text as of 25/5/2022
After India-Aus FTA, Indian pharma industry sees global opportunities
After the Comprehensive Economic Cooperation Agreement signed between India and Australia, the domestic pharmaceutical industry is seeing a plethora of opportunities for international trade.
An India-UK trade deal could mean a race to the bottom for Indian workers
On farmers and food, vaccine inequality, climate justice and digital rights, we need to act in solidarity – and not allow trade rules to sacrifice people to corporate profit.
World has moved on from US, EU’s drug monopoly. India and China are changing IP regulations
Even without an IP waiver from the WTO, China and India are leading the challenge to the West’s vaccine monopoly.
They concern you more than you know: On the perils and potential of international investment agreements for the Agreement on Trade-Related Aspects of Intellectual Property Rights and COVID-19 discussions at the World Trade Organization
Talks on a possible COVID-19-related TRIPS decision aimed at scaling up vaccine and therapeutics production and equitable distribution continue but investment agreements are absent from them.
‘Clear risk’ UK joining Pacific trade deal will raise drug prices for NHS
There is evidence of a potential conflict between the CPTPP and the UK’s current system of market authorisation of generic and biosimilar drugs.
In memory of Heesob Nam, a patent attorney who fought against vaccine inequality until the end
Heesob Nam, a patent attorney who dedicated his life to preventing the monopoly of ’intellectual property’ by a few, passed away on May 10th.
TRIPS Waiver: A BIT of a challenge for India
Potential BIT claims by foreign pharmaceutical companies against India for the revocation, suspension or non-enforcement of IPRs could undermine the benefits of a potential TRIPS waiver.
Intellectual property and COVID-19 medicines: why a WTO waiver may not be enough
The COVID-19 pandemic, and the race to make vaccines and other useful technologies more accessible to people around the world, has once again highlighted the tension between intellectual property rights and the promotion of public health.
UK and EU pharma call for medicines to be prioritised in Brexit trade talks
They have both emphasised the need for trade talks to mitigate medicine supply chain disruptions following Brexit.
A new trend in trade agreements: Ensuring access to cancer drugs
People around the world need to be aware of precedents in recent trade agreements and ensure that they also work for access to medicines for their own citizens.
Vietnam courts EU investment in medical and drug supply chains
Vietnam seeks to build on its new free trade agreement with the European Union to expand foreign investment in medical equipment and pharmaceuticals, with the government position the country as an alternative production base to China.
India, US trade deal: New Delhi seeks preferential treatment on drugs, other goods
India is seeking concessions for generic drugs it exports to the United States in return for opening its dairy markets and slashing tariffs on farm goods as the two sides seek to shore up a new trade deal.
Union calls for equal recognition for healthcare workers
The union and its allies also asked the government not to join the Trans-Pacific Partnership, as they view that the restriction of rights to access medicine under the deal would put the country’s public health system in danger.
If the government doesn’t halt trade talks with Trump, it’s learned nothing from coronavirus
The US trade model is not only unpopular with the British public, but it will also make us more vulnerable to future pandemics.
Covid-19: Why India doesn’t need to worry about investor-State dispute settlement claims
In order to halt the spread of the coronavirus pandemic (Covid-19) and to boost the public health care system and preparedness, India has taken several regulatory steps.
The Comprehensive and Progressive Agreement for the Trans-Pacific Partnership: Data exclusivity and access to biologics
The agreement does not promise that the suspended provision on test data rule concerning biological medicines will remain suspended.
Intellectual property rights: Potential implications of the DCFTA for access to medicine
If the intellectual property provisions of the DCFTA are applied, this will have an impact on both the cost of patented medicines and undermine access to affordable medicines.